Paper33323971
Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
Periyasamy M and 12 others. Oncogene, 2021. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB. Papers, record 33323971. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33323971
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytidine Deaminase | Major topic |
| Minor Histocompatibility Antigens | Major topic |
| Neoplasms | Major topic |
| Transcription Factor RelA | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Ataxia Telangiectasia Mutated Proteins | |
| CRISPR-Cas Systems | |
| Cisplatin | |
| DNA Repair | |
| Etoposide | |
| Fluorouracil | |
| Gene Expression Regulation, Neoplastic | |
| Genetic Heterogeneity | |
| HCT116 Cells | |
| Humans | |
| MCF-7 Cells | |
| Mutation | |
| NF-kappa B |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 12011 | Cancer Research UK | United Kingdom | PubMed | |
| 18784 | Cancer Research UK | United Kingdom | PubMed | |
| 23464 | Cancer Research UK | United Kingdom | PubMed | |
| A18784 | Cancer Research UK | United Kingdom | PubMed |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27283515 | The APOBEC Protein Family: United by Structure, Divergent in Function. | Trends Biochem Sci | 2016 | https://conductscience.org/library/papers/27283515 | PubMed |
| 2 | 29324969 | Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29324969 | PubMed |
| 3 | 22645179 | APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. | Blood | 2012 | https://conductscience.org/library/papers/22645179 | PubMed |
| 4 | 23599896 | DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. | Elife | 2013 | https://conductscience.org/library/papers/23599896 | PubMed |
| 5 | 23852168 | Evidence for APOBEC3B mutagenesis in multiple human cancers. | Nat Genet | 2013 | https://conductscience.org/library/papers/23852168 | PubMed |
| 6 | 23852170 | An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. | Nat Genet | 2013 | https://conductscience.org/library/papers/23852170 | PubMed |
| 7 | 23389445 | APOBEC3B is an enzymatic source of mutation in breast cancer. | Nature | 2013 | https://conductscience.org/library/papers/23389445 | PubMed |
| 8 | 25301630 | Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. | Science | 2014 | https://conductscience.org/library/papers/25301630 | PubMed |
| 9 | 30412573 | Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations. | PLoS Genet | 2018 | https://conductscience.org/library/papers/30412573 | PubMed |
| 10 | 30840888 | APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. | Cell Rep | 2019 | https://conductscience.org/library/papers/30840888 | PubMed |
| 11 | 27730215 | The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. | Sci Adv | 2016 | https://conductscience.org/library/papers/27730215 | PubMed |
| 12 | 30226610 | APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance. | Oncol Rep | 2018 | https://conductscience.org/library/papers/30226610 | PubMed |
| 13 | 20308164 | Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. | Nucleic Acids Res | 2010 | https://conductscience.org/library/papers/20308164 | PubMed |
| 14 | 28977491 | p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. | Nucleic Acids Res | 2017 | https://conductscience.org/library/papers/28977491 | PubMed |
| 15 | 26411678 | APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. | Cell Rep | 2015 | https://conductscience.org/library/papers/26411678 | PubMed |
| 16 | 28232385 | The Cytidine Deaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53. | Mol Cancer Res | 2017 | https://conductscience.org/library/papers/28232385 | PubMed |
| 17 | 16818887 | Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16818887 | PubMed |
| 18 | 28904012 | Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity. | Genome Res | 2017 | https://conductscience.org/library/papers/28904012 | PubMed |
| 19 | 31563041 | The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities. | DNA Repair (Amst) | 2019 | https://conductscience.org/library/papers/31563041 | PubMed |
| 20 | 20062055 | APOBEC3 proteins mediate the clearance of foreign DNA from human cells. | Nat Struct Mol Biol | 2010 | https://conductscience.org/library/papers/20062055 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41651672 | Effects of thymidylate synthase inhibitors differ in genomic uracilation and mutagenic potential. | Life Sci Alliance | 2026 | https://conductscience.org/library/papers/41651672 | PubMed |
| 41055562 | RNase H-sensitive accumulation of APOBEC3B in a nucleolus after DNA damage. | Biosci Rep | 2025 | https://conductscience.org/library/papers/41055562 | PubMed |
| 40323013 | APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40323013 | PubMed |
| 37375731 | NF-κB in Cell Deaths, Therapeutic Resistance and Nanotherapy of Tumors: Recent Advances. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37375731 | PubMed |
| 37190094 | Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase. | Cells | 2023 | https://conductscience.org/library/papers/37190094 | PubMed |
| 36978147 | APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. | J Hematol Oncol | 2023 | https://conductscience.org/library/papers/36978147 | PubMed |
| 36478188 | Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/36478188 | PubMed |
| 36280735 | Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer. | Nat Genet | 2022 | https://conductscience.org/library/papers/36280735 | PubMed |
| 36249021 | APOBEC3B is overexpressed in cervical cancer and promotes the proliferation of cervical cancer cells through apoptosis, cell cycle, and p53 pathway. | Front Oncol | 2022 | https://conductscience.org/library/papers/36249021 | PubMed |
| 35626687 | Black Phosphorus Quantum Dots Enhance the Radiosensitivity of Human Renal Cell Carcinoma Cells through Inhibition of DNA-PKcs Kinase. | Cells | 2022 | https://conductscience.org/library/papers/35626687 | PubMed |
| 34751899 | Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells. | J Nat Med | 2022 | https://conductscience.org/library/papers/34751899 | PubMed |
| 34389714 | Genotoxic stress and viral infection induce transient expression of APOBEC3A and pro-inflammatory genes through two distinct pathways. | Nat Commun | 2021 | https://conductscience.org/library/papers/34389714 | PubMed |
| 34373568 | Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. | Br J Cancer | 2021 | https://conductscience.org/library/papers/34373568 | PubMed |
Genes49
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33323971
GET https://conductscience.org/api/papers/v1/33323971/references?page=2